The US Food and Drug Administration has approved lenvatinib (Lenvima) for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
The approval of lenvatinib was based on the demonstration of improved progression free survival (PFS) in a multicentre, double-blind, placebo-controlled trial (E7080-G00-303).
The trial enrolled 392 patients with locally recurrent or metastatic radioactive iodine-refractory differentiated thyroid cancer and radiographic evidence of disease progression within 12 months prior to randomisation.
Patients were randomised (2:1) to receive either lenvatinib 24 mg orally per day (n = 261) or matching placebo (n = 131).
Patients in the placebo arm were allowed to receive lenvatinib following independent radiologic confirmation of disease progression.
A statistically significant prolongation of PFS as determined by independent radiology review was demonstrated [HR 0.21 (95% CI: 0.16, 0.28); p < 0.001, stratified log-rank test].
Median PFS was 18.3 months in the lenvatinib arm and 3.6 months in the placebo arm.
Objective response rates were 65% and 2% in the lenvatinib and placebo arms, respectively.
No statistically significant difference in overall survival between the two arms was demonstrated.
Upon confirmation of progression, 109 (83%) patients randomly assigned to placebo received open-label lenvatinib.
The most common adverse reactions, in order of decreasing frequency, observed in the lenvatinib treated patients were hypertension, fatigue, diarrhoea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia (PPE) syndrome, abdominal pain, and dysphonia.
The most common serious adverse reactions were pneumonia (4%), hypertension (3%), and dehydration (3%).
Adverse reactions led to dose reductions in 68% of patients receiving lenvatinib and 18% of patients discontinued lenvatinib for adverse reactions.
The recommended dose of lenvatinib is 24 mg taken orally once daily.
Treatment should continue until disease progression or unacceptable toxicity/
Click here for full prescribing information
For more ecancer coverage of lenvatinib in the treatment of thyroid cancer, see the interview or press conference with Prof Martin Schlumberger.
Source: FDA
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.